Mostrar el registro sencillo del ítem
O-5. Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the phase 3 HIMALAYA study
dc.contributor.author | Vogel, A. | |
dc.contributor.author | Chan, S. | |
dc.contributor.author | Furuse, J. | |
dc.contributor.author | Tak, W. | |
dc.contributor.author | Masi, G. | |
dc.contributor.author | Varela Calvo, María | |
dc.contributor.author | Kim, J. | |
dc.contributor.author | Tanasanvimon, S. | |
dc.contributor.author | Reig, M. | |
dc.contributor.author | Dayyani, F. | |
dc.contributor.author | Makowsky, M. | |
dc.contributor.author | Marcovitz, M. | |
dc.contributor.author | Negro, A. | |
dc.contributor.author | Abou Alfa, G. | |
dc.date.accessioned | 2023-03-15T10:33:39Z | |
dc.date.available | 2023-03-15T10:33:39Z | |
dc.date.issued | 2022 | |
dc.identifier.issn | 0923-7534 | |
dc.identifier.issn | 1569-8041 | |
dc.identifier.uri | http://hdl.handle.net/10651/66955 | |
dc.description | Resumen presentado al World Congress on Gastrointestinal Cancer (24th. 2022. Barcelona) | |
dc.description.sponsorship | AstraZeneca | |
dc.format.extent | p. S380-S381 | |
dc.language.iso | eng | |
dc.relation.ispartof | Annals of oncology | |
dc.rights | © 2022 European Society for Medical Oncology. Published by Elsevier Ltd. | |
dc.source | WOS:000823826500369 | |
dc.title | O-5. Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the phase 3 HIMALAYA study | |
dc.type | conference output | spa |
dc.identifier.doi | 10.1016/j.annonc.2022.04.446 | |
dc.relation.publisherversion | http://dx.doi.org/10.1016/j.annonc.2022.04.446 |
Ficheros en el ítem
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |